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Abstract
Matrix metalloproteinase 10 (MMP-10; stromelysin 2) is a member of a large family of structurally related matrix
metalloproteinases, many of which have been implicated in tumor progression, invasion and metastasis. We recently
identified Mmp10 as a gene that is highly induced in tumor-initiating lung bronchioalveolar stem cells (BASCs) upon
activation of oncogenic Kras in a mouse model of lung adenocarcinoma. However, the potential role of Mmp10 in lung
tumorigenesis has not been addressed. Here, we demonstrate that Mmp10 is overexpressed in lung tumors induced by
either the smoke carcinogen urethane or oncogenic Kras. In addition, we report a significant reduction in lung tumor
number and size after urethane exposure or genetic activation of oncogenic Kras in Mmp10 null (Mmp10
2/2) mice. This
inhibitory effect is reflected in a defect in the ability of Mmp10-deficient BASCs to expand and undergo transformation in
response to urethane or oncogenic Kras in vivo and in vitro, demonstrating a role for Mmp10 in the tumor-initiating activity
of Kras-transformed lung stem cells. To determine the potential relevance of MMP10 in human cancer we analyzed Mmp10
expression in publicly-available gene expression profiles of human cancers. Our analysis reveals that MMP10 is highly
overexpressed in human lung tumors. Gene set enhancement analysis (GSEA) demonstrates that elevated MMP10
expression correlates with both cancer stem cell and tumor metastasis genomic signatures in human lung cancer. Finally,
Mmp10 is elevated in many human tumor types suggesting a widespread role for Mmp10 in human malignancy. We
conclude that Mmp10 plays an important role in lung tumor initiation via maintenance of a highly tumorigenic, cancer-
initiating, stem-like cell population, and that Mmp10 expression is associated with stem-like, highly metastatic genotypes in
human lung cancers. These results indicate that Mmp10 may represent a novel therapeutic approach to target lung cancer
stem cells.
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Introduction
Non-small cell lung cancer (NSCLC) is the most common cause
of cancer death in the United States [1]. Despite advances in
treatment, clinical outcome of lung cancer patients remains poor.
Therefore, there continues to be a need to identify underlying
mechanisms of lung tumorigenesis that could lead to more
effective means of prevention, diagnosis, prognosis and targeted
therapies.
Emerging evidence supports the existence of rare subpopula-
tions of cancer cells with stem-like characteristics [2,3,4]. These
cancer-initiating cells or cancer stem cells (CSCs) exhibit self-
renewal, tumor-initiating activity, and the ability to support tumor
maintenance and metastasis [2,4,5,6]. Thus, CSCs appear to be
critical targets for effective, potentially curative cancer treatment.
Unfortunately, CSCs exhibit intrinsic resistance to chemotherapy
[7,8], underlining the need to identify new therapeutic targets to
effectively eradicate CSCs. CSCs share molecular and genomic
features with embryonic stem cells, and embryonic stem cell
genomic signatures are enriched in highly tumorigenic cancer
stem cells. Such CSCs have been described in leukemia [9], and
solid tumors, including melanoma [10], breast [11], brain
[12,13,14], prostate [15], head and neck [16], pancreatic [17],
colon carcinomas [18,19], and lung [20,21].
We recently demonstrated that Mmp10 is required for the
transformed growth and invasion of human NSCLC cells in vitro
[22]. However, the role of Mmp10 in lung tumorigenesis has not
been addressed. Here, we use a combination of mouse carcinogen-
esis models and analysis of human tumors to demonstrate that
Mmp10 plays a novel, unexpected role in Kras-mediated lung cancer
initiation, lung cancer stem cell expansion, and metastasis. Our data
indicate that Mmp10 is an attractive therapeutic target for CSCs.
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Mmp10 loss inhibits Kras-mediated lung tumorigenesis
In order to determine whether Mmp10 is involved in lung tumor
formation, mice were treated with the smoke carcinogen urethane
to induce lung adenocarcinoma tumors using well-established
protocols [23]. Immunohistochemical analysis demonstrated that
Mmp10 expression is elevated in urethane-induced tumors,
particularly at areas of contact between the tumor and the
surrounding stroma (Figure 1A). These results are consistent with
previous observations in human NSCLC tumors [22,24,25].
Interestingly, when Mmp10
2/2 mice were exposed to urethane,
these mice developed significantly fewer (Figure 1B) and smaller
(Figure 1C) tumors, and exhibited a smaller total tumor
burden (Figure 1D) than non-transgenic (NTg) littermates.
Analysis of tumor grade using the system described by Kelly-
Spratt et al. [26] demonstrated that urethane-induced tumors
from Ntg and Mmp10
2/2 mice showed a similar distribution of
tumors along the hyperplasia-adenoma-carcinoma progression
scheme (Figure 1E). These data indicate that Mmp10 plays an
important promotive role in urethane-induced lung tumorigenesis
primarily at the tumor initiation stage.
Since urethane-induced lung tumorigenesis is thought to be
driven, at least in part, through acquisition of Kras mutations, we
assessed whether Mmp10 plays a similar promotive role in Kras-
mediated lung tumorigenesis. For this purpose, we crossed
Mmp10
2/2 mice to Kras
LA mice, in which spontaneous recom-
bination events lead to activation of a mutant Kras
G12D allele in the
lung that drives lung tumor formation [27]. Lung tumors in Kras
LA
mice express elevated Mmp10 that exhibits a similar pattern of
expression as in urethane-induced lung tumors (Figure 2A).
Similar to our observation in urethane-treated mice, bitransgenic
Kras
LA2/Mmp10
2/2 mice developed fewer (Figure 2B) and
smaller (Figure 2C) tumors, and exhibit lower overall tumor
burden (Figure 2D) than Kras
LA2 mice. Analysis of tumor grade
using the scoring system devised by Jackson et al. [28]
demonstrated that ,16% of tumors in Kras
LA mice were high
grade adenocaricnomas (grade 3), whereas less than 1% of the
tumors in Kras
LA2/Mmp10
2/2 mice were grade 3 (Figure 2E).
These data suggest that Mmp10 in this model is important in both
tumor initiation and progression. Taken, together our data
indicate that Mmp10 plays an important role in multiple models
of lung tumor formation.
Mmp10 is required for Kras-mediated bronchio-alveolar
stem cell expansion in vivo
The fact that Mmp10-deficient mice develop fewer Kras-
mediated lung tumors suggests that Mmp10 is involved in the
initiating steps of Kras-mediated lung tumorigenesis in vivo.
Initiation of Kras-mediated lung tumors is thought to involve
clonal expansion of Kras-transformed bronchio-alveolar stem cells
(BASCs), putative regional stem cells that reside at the terminal
bronchioles adjacent to the alveolar space [29]. Therefore, we
assessed whether Mmp10-deficiency affects the expansion of
BASCs in response to urethane and oncogenic Kras in vivo.W e
identified and quantitated BASCs in paraffin sections of mouse
lungs by dual immunofluorescence staining for surfactant protein
C (SPC) and the Clara cell-specific protein (CCSP) as described
previously [29,30]. BASCs are observed at the bronchioalveolar
duct junctions at terminal bronchioles as double SPC/CCSP
positive cells (Figure 3A). Either urethane treatment or the
presence of oncogenic Kras caused an expansion of BASCs at the
terminal bronchioles (Figure 3A). Quantitative analysis of lung
tissue sections from Ntg and Mmp10
2/2 mice in the absence or
presence of urethane showed that urethane-treated Ntg mice
exhibit a significant increase in the number of BASC per terminal
bronchiole (BASCs/TB) when compared with control Ntg mice
(Figure 3B). Urethane-treated Mmp10
2/2 mice showed a highly
significantly diminiution in BASC expansion, such that the
distribution and number of BASCs was not significantly different
from untreated Ntg mice (Figure 3B). A similar inhibition of
oncogenic BASC expansion was observed in Kras
LA2/Mmp10
2/2
mice in vivo when compared to Kras
LA2 mice (Figure 3C).
Therefore, in two independent models of Kras-mediated lung
tumorigenesis, we observed that Mmp10 deficiency leads to
significant decreases in lung tumor number, size and burden;
and in each model, the inhibitory effect of Mmp10 deficiency on
tumorigenesis was reflected in a defect in the oncogenic expansion
of BASCs in vivo. Interestingly, Mmp10 deficiency does not appear
to have an effect on BASC homeostasis per se since BASC number
and distribution in Mmp10
2/2 mice is not significantly different
from that of Ntg mice. Rather, Mmp10 appears to be important
for oncogenic expansion of BASCs in response to urethane or Kras
activation.
Mmp10 is required for Kras-mediated BASC
transformation in vitro
Given the importance of BASCs in tumor initiation, and the
inhibitory effect of Mmp10 loss on Kras-mediated BASC expansion
in vivo, we assessed the role of Mmp10 in Kras-mediated BASC
expansion and transformation in vitro. For this purpose, we utilized
LSL-Kras mice, a model in which a conditional lox-stop-lox (LSL)
Kras allele can be activated by Cre-mediated recombination [31].
BASCs were isolated from Ntg, LSL-Kras, and LSL-Kras/Mmp-
10
2/2 mice and characterized for enrichment of BASCs using
dual immunofluorescence and flow cytometry. Our BASC
preparations consisted of .86% SPC/CCSP double positive cells
when analyzed by flow cytometry confirming isolation of a highly
enriched BASC population (Figure 4A). Treatment of BASCs
from LSL-Kras mice with adenovirus expressing Cre-recombinase
(AdCre) to activate the oncogenic Kras allele led to a significant
increase in Mmp10 mRNA abundance, whereas AdCre-treated
BASCs from LSL-Kras/Mmp10
2/2 mice expressed no detectable
Mmp10 mRNA as expected (Figure 4B). These results confirm
our previous finding that Mmp10 expression is induced in BASCs
after expression of oncogenic Kras [30]. AdCre treated BASCs
from Ntg or Mmp10
2/2 mice form small, highly organized
spherical colonies when plated in three dimensional Matrigel
culture of similar size and number (Figure 4C). In contrast,
AdCre treated BASCs from LSL-Kras mice grow as larger
amorphic, disorganized colonies characteristic of Kras-mediated
transformation (Figure 4C, middle panel; [30]). AdCre treated
BASCs from LSL-Kras/Mmp10
2/2 mice form colonies similar in
size, number and morphology to those from Ntg and Mmp10
2/2
mice (Figure 4C). Quantitative analysis confirmed that BASC
colonies from LSL-Kras mice are of larger diameter than colonies
from Ntg, Mmp10
2/2 or LSL-Kras/ Mmp10
2/2 BASCs
(Figure 4D). Thus, Mmp10 is required for oncogenic Kras-
induced morphological transformation and expansion of BASCs in
vitro but has no appreciable effect on the maintenance of non-
transformed BASCs in culture.
Mmp10 expression is associated with stem cell
signatures and metastasis in human lung cancer
We previously demonstrated that Mmp10 is overexpressed in
human NSCLC and is important for transformed growth and
invasion of human NSCLC cells in vitro [22]. Given the
Mmp10 Is Critical for Lung Tumor Initiation
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26439Figure 1. Mmp10 plays a promotive role in urethane-induced lung tumorigenesis. Mmp10
2/2 mice and Ntg littermates were injected with
urethane and analyzed as described in Materials and Methods. A) H & E and immunohistochemical staining for Mmp10 in urethane-induced lung
tumors. Higher magnification image of Mmp10 immunostaining is shown in the inset. Quantitative analysis of tumor number B), tumor size C) and
tumor burden D) in urethane-treated Ntg (n=7) and Mmp10
2/2 (n=12) mice. Mean +/2SEM; p,. 0.012 tumor number; p,0.019 tumor burden;
p=0.034 tumor size). E) Urethane-induced tumors from Ntg and Mmp10
2/2 mice were graded as hyperplasia, adenoma or adenocarcinoma using
published criteria [26]. Results are presented as the percentage of total tumors of each grade. Statistical analysis using Mann-Whitney U test revealed
no statistically significant difference in tumor grade between urethane-induced tumors in Ntg and Mmp10
2/2 mice (p=0.39).
doi:10.1371/journal.pone.0026439.g001
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mouse lung BASC and tumor initiating activity, we computation-
ally explored the relationship between Mmp10 expression, cancer
stem cell expression profiles and metastasis in human lung cancers.
For this purpose, we divided a publicly-available dataset consisting
of genome-wide expression analysis of human lung adenocarcino-
mas (GSE11969) into two equal sized groups of 30 samples
comprised of the tumors with the highest (High) and lowest (Low)
Figure 2. Mmp10 is necessary for Kras
LA2-induced lung tumorigenesis in vivo. A) Immunohistochemical staining of Kras
LA2 lung tumor for
mouse MMP10. Higher magnification image of Mmp10 immunostaining is shown in the inset. Quantitative analysis of B) tumor number, C) tumor
size and D) tumor burden in Kras
LA2 and Kras
LA2/Mmp10
2/2 mice. Columns, mean; bars, SEM, n=13, (*) denotes p=0.04. E) Tumors from Kras
LA2 and
Kras
LA2/Mmp10
2/2 mice were categorized as advanced adenomatous hyperplasia (AAH), or grade 1,2 or 3 adenomas using the published scoring
criteria described by Jackson et al. [28]. Results are presented as the percentage of total tumors of each grade. Statistical analysis using Mann-Whitney
U test revealed a significant decrease in higher grade tumors in Kras
LA2/Mmp10
2/2 mice; *p,0.002.
doi:10.1371/journal.pone.0026439.g002
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firmed these two groups of samples express significantly different
levels of Mmp10 mRNA (Figure 5A). We then performed gene
set enrichment analysis (GSEA) against gene sets available as part
of the Molecular Signatures Database (MSig) Version 3.0 as
described in Materials and Methods to measure any association
between Mmp10 and cancer stem cell gene expression profiles.
Gene sets were identified by searching the MSig database for gene
signatures containing the terms ‘‘cancer’’ and ‘‘stem’’ within their
descriptions. GSEA revealed that 37 of the 50 (74%) cancer stem
cell signatures were enriched in the high Mmp10 samples, and that
14 signatures were significantly enriched with a p-value ,0.05 and
FDR ,25% (Table 1). Interestingly, only 1/50 stem cell
signature was enriched in the low Mmp10 samples. This signature
described genes that are downregulated in glioma stem cells, [32],
further supporting the association of high Mmp10 with the cancer
stem cell genotype. A separate GSEA using an independent lung
adenocarcinoma gene expression data set (GSE13213) validated
our initial analysis. 44/50 stem cell signatures were enriched in
high Mmp10 tumor samples and none were enriched in the low
Mmp10 tumor samples from this second data set. 10 stem cell gene
sets were significantly enriched with a p-value ,0.05 (Table 2), of
which seven were also significantly enriched in the first lung
adenocarcinoma gene set. These data provide compelling
evidence that high Mmp10 expression in human NSCLC tumors
is associated with a cancer stem-like gene expression profile.
We also performed an unbiased analysis using every gene set in
the MSig database. In this analysis, the top stem cell signatures
remained significantly enriched (data not shown). Table 3 shows the
most highly significant gene signatures associated with high
Mmp10. Significantly, 3 of the top 5 gene sets identified contain
Mmp10 as part of the signature. The top scoring gene set describes
a signature comprised of genes over-expressed in early stage head
and neck tumors suggesting an involvement in early tumorigenesis
[33]. Among the gene sets that significantly correlate with high
Mmp10 expression, many related to tumor progression, poor
clinical outcome and metastatic potential. To specifically explore
the association between Mmp10 and lung tumor metastasis, we
analyzed a third gene expression dataset from early stage human
lung adenocarcinoma samples that had produced a metastasis in
bone tissue compared to samples that had not [34]. Analysis
revealed that Mmp10 expression was significantly elevated in the
primary tumors that produced metastases when compared to
normal lung tissue but not in those that did not, indicating an
association between Mmp10 expression and metastatic potential
(Figure 5B). Interestingly, GSEA of the metastatic lung cancer
gene set demonstrated a highly significant correlation with 10 stem
cell signatures (p-value ,0.05 and FDR ,25%), four of which
were also among the most significant gene sets identified using
GSEA of the high Mmp10 lung adenocarcinomas (Table 4).
These latter results reveal an association between metastatic
potential and stem-like characteristics in primary human lung
adenocarcinomas.
Given the importance of elevated Mmp10 expression in human
lung cancer biology, we next assessed whether Mmp10 expression
was also elevated in other forms of human cancer. Gene
expression profiling revealed that Mmp10 is commonly overex-
pressed in many forms of human cancer, including lung, head and
neck, esophageal, bladder, skin, colorectal, breast, cervical,
nasopharyngeal, tongue and pancreatic cancers (Figure 5C and
Table 5), suggesting a widespread role for Mmp10 in human
malignancy.
Discussion
Increasing evidence suggests that many cancers, including lung
cancer, possess a small subpopulation of cells that exhibit hallmark
traits of stem cells. These ‘‘cancer stem cells’’ are thought to be
Figure 3. MMP10 is required for urethane- and Kras-induced
BASC expansion in vivo.A ) Immunofluorescent analysis of CCSP
(green) and SPC (red) dual positive BASCs (white arrows) in terminal
bronchioles(TB)ofcontrolNtg,andurethane-treatedNtgandMmp10
2/2
mice (upper panels), and from Ntg, Kras
LA2 and Kras
LA2/Mmp10
2/2 mice
(lower panels). B) Quantitative analysis of BASCs in control Ntg, and
urethane treated Ntg and Mmp10
2/2 mice. %TBs; bars +/2SEM, n=$30
TBs/genotype. p,0.0005 urethane treated NTg vs. Mmp10
2/2;p ,0.0001
untreated Ntg vs. urethane-treated Ntg; No significant difference
between untreated non-Ntg vs. urethane treated Mmp10
2/2 mice. C)
Quantitative analysis of BASCs in lung TBs of Ntg, Kras
LA2 and Kras
LA2/
Mmp10
2/2 mice. Columns, percentage of TBs; bars =/2SEM, n$50 TBs/
genotype; p,0.001 Ntg vs. Kras
LA mice; p,0.003 Kras
LA mice vs. Kras
LA2/
Mmp10
2/2 mice;nosignificantdifferenceinBASC number or distribution
was observed between Ntg and Kras
LA2/Mmp10
2/2 (p=0.76) or
Mmp10
2/2 (p=0.76) mice.
doi:10.1371/journal.pone.0026439.g003
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metastatic spread of tumors. Most current treatment modalities
for lung cancer ultimately fail, perhaps due to intrinsic resistance
of CSCs to therapy, resulting in disease recurrence and decreased
patient survival. Therefore, molecular characterization of the
mechanisms that govern the survival and growth of CSCs may
hold a vital key to developing more effective therapeutic strategies
that will improve the clinical outcome of patients with lung cancer.
The matrix metalloproteinases (MMPs) have long been
implicated in tumor progression and metastasis. We recently
demonstrated that Mmp10 is overexpressed in NSCLC and is a
critical target of oncogenic Kras required for transformed growth
and invasion of human NSCLC cells in vitro [22]. Our current
study provides compelling evidence that Mmp10 exerts its pro-
tumorigenic effects, at least in part, by maintaining a population of
CSCs that drive tumor initiation and metastasis. Not only is
Mmp10 elevated in tumors developed in two different mouse
models of Kras-induced lung adenocarcinoma, genetic knock out of
Mmp10 leads to formation of significantly fewer tumors, suggesting
an effect of Mmp10 on tumor initiation. Consistent with this
conclusion, Mmp10 abundance is highly elevated in BASCs
transformed with oncogenic Kras [30], and genetic loss of Mmp10
leads to a failure of BASCs expressing oncogenic Kras to expand in
vivo, and undergo morphological transformation in vitro. Though it
is still unclear whether BASCs represent regional lung stem cells,
strong circumstantial evidence indicates that they are involved in
tumor initiation in the mouse lung. BASCs undergo expansion and
transformation in response to Kras activation [29], and genetic
and/or pharmacological disruption of multiple key oncogenic
pathway genes involved in Kras-mediated tumorigenesis, including
Prkci [30], Pik3ca [35], and Bmi1 [36], lead to inhibition of BASC
expansion and Kras-mediated tumor formation in vivo. On the
other hand, recent studies have demonstrated that both Sca1
+
(including BASCs) and Sca1
- cells exhibit tumor-initiating activity
in Kras mice, demonstrating that BASCs are not the sole source of
tumor-initiating cells in this model [37]. These findings indicate
Figure 4. Mmp10 is required for Kras-induced expansion and transformation of BASCs in vitro. BASCs isolated from Ntg, Mmp10
2/2, LSL-
Kras, and LSL-Kras/Mmp10
2/2 mice were treated with AdCre and plated in three-dimensional Matrigel culture as described in Experimental Procedures.
A) Flow cytometry of isolated BASCs for SPC and CCSP B) QPCR for Mmp10 in BASCs from Ntg, LSL-Kras, and LSL-Kras/Mmp10
2/2 mice. Fold of Ntg +/
2SEM. n=3, *p,0.000008. C) Morphology of BASC colonies from Ntg, Mmp10
2/2,LSL-Kras, and LSL-Kras/Mmp10
2/2 mice. D) Analysis of BASC colony
size. %Ntg +/2SEM. n=85 Ntg, 56 Mmp10
2/2,30 (LSL-Kras) and 80 (LSL-Kras/Mmp10
2/2). *p,0.00001 Ntg vs, LSL-Kras; **p,0.00001 LSL-Kras vs. LSL-
Kras/Mmp10
2/2.
doi:10.1371/journal.pone.0026439.g004
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initiating cells. In humans, lung adenocarcinomas, which fre-
quently harbor Kras mutations, often develop at the bronchio-
alveolar duct junction and display either airway or alveolar
differentiation, or both [38], suggesting that some of these tumors
may have originated from BASC-like cells.
Our data provide evidence that the role of Mmp10 in lung CSCs
is cell autonomous. Both the Kras
LA2 and urethane tumor models
show Mmp10 staining in tumor cells, with little to no staining in
tumor associated-stroma or morphological normal lung epitheli-
um. More importantly, the tumor inhibitory effects of the genetic
loss of Mmp10 are reflected in a defect in oncogenic expansion of
BASCs in vivo and in vitro. Thus, while many MMPs produced by
the tumor microenvironment play prominent roles in the invasive
and metastatic properties of lung tumor cells, our data
demonstrate that Mmp10 specifically functions to support the
autonomous growth of CSCs. However, our data do not exclude a
contributory role for Mmp10 produced by and/or exerting its
effects upon the tumor microenvironment. However, our studies
do provide new insight into a largely unappreciated role for
Mmp10 in the regulation of CSC behavior. Interestingly, Mmps
have been implicated in regulation of tumor cell growth through
cleavage and activation of cell surface proteins involved in cell
growth regulation such as Notch [39,40], and through proteolytic
Figure 5. Mmp10 expression correlates with cancer stem cell genotypes and metastasis in human lung tumors. A) Gene expression
data from primary human lung adenocarcinomas were divided into two groups of 30 samples consisting of lowest (Low) and highest (High) Mmp10
expressing lung tumors. n=30; * p=2.8610
233. B) Mmp10 in normal lung versus lung tumors with (Met.) and without (No Met.) bone metastases.
n=3, normals, n=9, No Mets, n=7, Met.; NS= not significant, *p=0.008; **p=0.04. C) Mmp10 mRNA expression in human tumors. Data are
expressed as fold-change from matched normal.
doi:10.1371/journal.pone.0026439.g005
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from latent extracellular stores [41]. Future studies will focus on
determining the specific molecular mechanisms that contribute to
Mmp10-mediated CSC proliferation.
Cancer stem cells (CSCs) are defined by their ability to clonally
expand, initiate tumors, maintain tumor progression and partic-
ipate in tumor metastasis. The phenotype of these cells is
associated with a genotype related to that of embryonic stem
cells. Our finding that Mmp10 expression is associated with CSC
genotypes in human lung tumors provides compelling circum-
stantial evidence that Mmp10 plays a critical role in maintenance
of CSCs within human lung tumors. In this regard, it is interesting
to note that Mmp10 expression has been observed to be elevated
in tumor-initiating stem-like cells isolated from human small cell
lung cancer cell lines [42], suggesting that Mmp10 may also
function in the maintenance of these CSCs.
The leading cause of cancer-related deaths in lung cancer
patients is metastatic dissemination. CSCs are thought to be the
cells within a tumor that have the capability of metastasizing to
distant sites. Our finding that Mmp10 is highly expressed in lung
cancer-initiating BASCs, and is associated with the CSC genotype
in human lung tumors suggests that Mmp10 may promote both
CSC maintenance and metastatic potential through its role in
CSC proliferation and metastatic behavior. Our finding that
Mmp10 is elevated in human CSCs and that Mmp10 is highly
expressed at the interface between mouse lung tumors and the
surrounding tissue, suggesting a role for Mmp10 in tumor
invasion, and are consistent with our previous funding that
Mmp10 is required for invasion of human NSCLC cells in vitro
[22]. These areas of increased Mmp10 staining may represent
resident CSCs. The fact that Mmp10 is more highly expressed in
tumors with high metastatic potential, and in the metastatic lesions
of these tumors is consistent with the proposed role of CSC in
metastatic spread. However, we cannot formally rule out an
additional role for Mmp10 in bulk tumor cells that contributes to
the metastatic potential of tumors. Our expression profiling data of
human tumors demonstrates a close functional link between CSC,
Mmp10 expression and metastatic potential, suggesting that
Mmp10 plays a similar role in human lung adenocarcinoma
CSC invasion and metastasis. Our results also demonstrate that
Table 1. Cancer Stem Cell Signatures correlate with high Mmp10 expression in lung cancer.
Signature Name/Description Size (genes) ES NES P-value FDR Reference
Embryonic Stem Cell (ESC)-proliferation 111 0.44 2.11 ,0.0001 0.003 [54]
ESC-Core signature 268 0.34 1.86 ,0.0001 0.015 [55]
ESC-gene set 1 285 0.3 1.65 ,0.0001 0.059 [54]
ESC-NOS targets 136 0.3 1.48 0.014 0.156 [54]
ESC-PRC2 targets 489 0.24 1.4 0.002 0.23 [54]
ESC-SUZ12 targets 765 0.23 1.38 ,0.0001 0.23 [54]
ESC-Oct4 targets 228 0.25 1.35 0.023 0.21 [54]
ESC- EED targets 778 0.21 1.29 0.002 0.21 [54]
ESC-cycling genes 460 0.22 1.25 0.027 0.24 [54]
Breast cancer progenitor cells 266 0.24 1.32 0.021 0.22 [56]
ESC-H3K27 ME3 830 0.21 1.29 0.002 0.23 [54]
ESC-Myc-Max targets 653 0.21 1.24 0.015 0.23 [54]
ESC-Sox2 targets 509 0.21 1.22 0.018 0.22 [54]
ESC-Nanog targets 694 0.2 1.17 0.036 0.25 [54]
doi:10.1371/journal.pone.0026439.t001
Table 2. Validation of the association between high Mmp10 in lung tumors and cancer stem cell signatures.
Gene Set Size (genes) ES NES p-value Reference
ESC-Proliferation 143 0.5 2.14 ,0.0001 [54]
Breast cancer progenitor cells UP 370 0.38 1.8 ,0.0001 [56]
Breast cancer-tamoxiphen resistance 49 0.49 1.72 0.025 [57]
UV response cluster G4 13 0.65 1.72 0.044 [58]
ESC-ES geneset 1 370 0.33 1.56 0.004 [54]
Leukemic stem cells 234 0.34 1.53 0.007 [59]
ESC-EED Targets 1002 0.26 1.36 0.009 [54]
ESC-cycling genes 630 0.26 1.32 0.023 [54]
ESC-H3K27ME3 1058 0.24 1.25 0.018 [54]
ESC-SUZ12_Targets 979 0.24 1.25 0.037 [54]
Gene sets marked in bold text were also significantly enriched in the high Mmp10 lung tumor gene set analysis outlined in Figure 5 and Table 1.
doi:10.1371/journal.pone.0026439.t002
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26439MMP10 is highly expressed in many human tumor types, and is
associated with poor outcome, metastatic potential and cancer
stem cell signatures. These findings suggest a widespread role for
Mmp10 in human malignancy and identify Mmp10 as a novel
therapeutic target in cancer stem cells.
Materials and Methods
Mouse Urethane- and Kras
LA2-mediated Lung
Tumorigenesis Studies
Nullizygous Mmp10 (Mmp10
2/2)m i c ew e r eo b t a i n e df r o m
the National Cancer Institute Mutant Mouse Regional
Resource Center (MMRRC). The mice were generated on a
mixed 129/C57BL/6J background and harbor a targeted
disruption of exons 1–3 of the mouse Mmp10 gene. The mice
were bred onto a pure C57BL/6J background through 10
generations. Genotyping was conducted by PCR using primers
recommended by MMRRC. Mmp10
2/2 mice and non-
transgenic littermates were injected intraperitoneally with
urethane at 1 mg/kg body weight weekly for six weeks to
induce lung tumors. Control mice were injected with saline.
Mice were analyzed twelve weeks after the first injection for the
presence of pulmonary lesions. Kras
LA2 mice, generated as
previously described [27], were mated with Mmp10
2/2 mice to
generate bitransgenic Kras
LA2/Mmp10
2/2 mice. Kras
LA2 and
Kras
LA2/Mmp10
2/2 mice were harvested at the time points
indicated to assessed tumor number, tumor size, tumor burden
and pathological classification by a board-certified pathologist
(A.K.). Mmp10
2/2 and non-transgenic mice served as negative
controls. All animal experiments were approved by the
Institutional Animal Care and Use Committee of Mayo Clinic
and were conducted under approved IACUC protocol#
A30308. Mouse tissues were prepared for histology and
immunohistochemistry as previously described [30,43]. Sec-
tions were stained for Mmp10 (NBP1-03118; Novus Biologicals,
Littleton, CO) and antigen visualized using the Envision Plus
Table 3. The 10 most highly correlated signatures associated with high Mmp10 in lung cancer.
Gene Set Name Size (genes) ES NES p-value FDR Reference
Upregulated in early stage Head
and Neck tumors vs. normal
43 0.75 2.65 ,0.0001 ,0.0001 [33]
Up regulated in colon adenomas
vs. normal mucosa
128 0.6 2.51 ,0.0001 0.001 [60]
Upregulated in breast cancer 19 0.85 2.41 ,0.0001 0.009 [61]
Up regulated in basal mammary
epithelial cells vs. luminal
53 0.67 2.4 ,0.0001 0.007 [62]
Upregulated in cervical cancers and associated
with proliferation and pooor outcome
140 0.56 2.38 ,0.0001 0.011 [63]
Upregulated in NSCLC and predict poor survival 445 0.48 2.37 ,0.0001 0.012 [64]
Up regulated in in advanced vs early gastric cancers 162 0.55 2.35 ,0.0001 0.016 [65]
Up regulated in nasopharyngeal carcinoma vs. normal 272 0.5 2.31 ,0.0001 0.026 [66]
Up regulated in invasive ductal breast carcinoma
vs. carcinoma in situ
343 0.49 2.31 ,0.0001 0.024 [67]
Up regulated in breast ductal carcinoma vs. normal 66 0.6 2.3 ,0.0001 0.024 [68]
Gene sets marked in bold text contain Mmp10 as part of the gene signature.
doi:10.1371/journal.pone.0026439.t003
Table 4. Association of metastatic lung cancer genes with cancer stem cell signatures.
Gene Set Size (genes) ES NES p-value FDR Reference
UV Response Cluster G4 14 0.67 1.86 0.005 0.015 [58]
Response to UV NHEK UP 146 0.41 1.82 ,0.0001 0.012 [58]
UV Response Cluster G3 11 0.66 1.68 0.011 0.043 [58]
Silenced by Methylation in Colon Cancer 42 0.44 1.58 0.015 0.08 [69]
TP63 Gamma Targets 9 0.65 1.57 0.035 0.069 [70]
ESC-EED Targets 921 0.29 1.51 ,0.0001 0.107 [54]
Cancer Progenitors 61 0.37 1.45 0.025 0.129 [54]
ESC-PRC2 Targets 566 0.28 1.44 ,0.0001 0.124 [54]
ESC with H3K27ME3 991 0.27 1.44 ,0.0001 0.111 [54]
ESC SUZ12 Targets 906 0.25 1.33 ,0.0001 0.222 [54]
Gene sets marked in bold text are cancer stem cell signatures also identified as highly correlated with lung tumors expressing high Mmp10.
doi:10.1371/journal.pone.0026439.t004
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using the ScanScope scanner and ImageScope software (Aperio
T e c h n o l o g i e s ,V i s t a ,C A ) .
BASC detection, isolation and culture ex vivo
BASCs were quantified in formalin fixed, paraffin embedded
mouse lung tissues as described previously [30,35]. LSL-Kras mice
[44] were crossed with Mmp10
2/2 mice to generate bitransgenic
LSL-Kras/Mmp10
2/2 mice. Lung epithelial cells were isolated
from Ntg, Mmp10
2/2, LSL-Kras, and LSL-Kras/Mmp10
2/2 mice
and BASC isolation, Cre-recombinase treatment and ex vivo
culture were carried out as described previously [30]. Brightfield
images of BASC colonies were captured on an Olympus IX71
inverted microscope. BASC colony size was assessed using Image-
Pro Plus 6.3 (Media Cybernetics, Bethesda, MD). BASCs were
recovered from Matrigel culture for QPCR analysis using BD cell
recovery solution (BD Biosciences).
RNA isolation and quantitative PCR
Total RNA was extracted from BASC cells using the RNeasy
Plus Mini Kit (Qiagen, Valencia, CA). QPCR reagents for mouse
Mmp10 mRNA were purchased from Applied Biosystems (Foster
City, CA). QPCR was carried out using an Applied Biosystems
7900 thermal cycler, and data was analyzed using the SDS 2.3
software package. Data were normalized to 18S RNA.
Flow cytometry
BASCs were incubated for 1 hour at 4uC with Alexa Fluor 488-
conjugated CD133 (Millipore, Billerica, MA) and Alexa Fluor 647
conjugated Notch4 (Biolegend, San Diego, CA) antibodies or
respective isotype controls. Cells were incubated for 1 hour at 4uC
with CCSP (Upstate, Temecula, CA) and SPC (Santa Cruz
Biotechnology, Santa Cruz, CA) antibodies followed by a 30
minute incubation with Alexa Fluor 488- and Alexa Fluor 647
conjugated secondary antibodies (Invitrogen, Carlsbad, Califor-
nia). Flow cytometry was performed on an Accuri C6 flow
cytometer and analyzed using CFlow Plus software (Accuri
Cytometers, Inc., Ann Arbor, MI).
Statistical analysis
Differences in the number and distribution of BASCs in the
terminal bronchioles were assessed using the Cochrane-Armitage
test using StatsDirect 2.6.1. Differences in tumor grade were
assessed using the Mann-Whitney U test in Stats-Direct 2.6.1. The
Student’s t test and one-way ANOVA statistical analyses were
done using SigmaStat 3.5. A P value of less than 0.05 was
considered statistically significant.
Assessment of Mmp10 in primary human cancer datasets
The correlation between Mmp10 and various types of human
cancer was determined using the NextBio data mining framework
(www.nextbio.com) [45]. The degree of correlation calculated by
NextBio was based on Mmp10 values for individual microarray
studies of specific cancer types. Selected gene expression
experiments were chosen for a more in depth analysis The Gene
Expression Omnibus (GEO) accession numbers for these studies
were: GSE3292, GSE3292, GSE6631, GSE6059, GSE5364,
GSE14999, GSE3167, GSE13507, GSE7553, GSE7553,
GSE4183, GSE8671, GSE1987, GSE10799, GSE6791,
GSE18105, GSE11117, GSE13597, GSE9844, GSE23400,
Table 5. MMP10 is Overexpressed in many Human Cancer Types.
Tumor Type/Data set Description Tumor N Control N MMP10 T/N p-value Reference
Esophageal Cancer Esophageal Tumor vs. matched normal 13 13 4.56 0.0158 [71]
Breast Cancer Infiltrating ductal mammary carcinoma vs. normal 68 61 5.79 1.4E-15 [72]
Bladder Cancer Muscle Invasive Carcinoma vs. normal 13 9 4.54 0.0015 [73]
Bladder Cancer Primary Resected Bladder Tumor vs. normal 165 10 1.59 0.0006 [74]
*Skin Cancer Squamous cell carcinoma vs. normal 11 4 36 4.1E-07 [75]
*Skin Cancer Basal cell carcinoma vs. normal 15 4 24.7 4E-06 [75]
Colorectal Cancer Colon biopsies from colorectal carcinoma patients 15 8 5.7 0.0008 [76]
Colorectal Cancer Colorectal Adenoma vs. normal 32 32 5.2 5.4E-10 [60]
Lung Cancer Squamous cell carcinoma vs. normal 16 7 7.59 0.0002 [77]
Lung Cancer Adenocarcinoma vs. normal 7 2 2.64 0.034 [77]
Cervical Cancer HPV-positive cervical cancer vs. normal 20 8 7.09 8.4E-05 [78]
Colorectal Cancer metastatic-versus non-metastatic 77 N/A 2.29 0.04 [79]
Skin Cancer Melanoma vs. normal 14 4 5.9 0.0002 [80]
NSCLC stage T2 vs T1 41 15 24.2 0.007 [80]
NSCLC stage T4 vs T1 14 4 30.4 0.005 [80]
NSCLC N2 vs N0 9 13 7.38 0.027 [80]
NSCLC M1 vs M0 17 24 4.4 0.025 [80]
Nasopharyngeal Cancer Nasopharyngeal Cancer biopsies vs. normal 25 3 4.41 2.10E-07 [81]
SCC of tongue SCC tongue vs. normal 26 12 6.33 1.30E-06 [82]
esophageal SCC vs matched normal 53 53 4.57 9.00E-10 [83]
NSCLC squamous cell (18) vs. adenocarcinoma (40) 18 40 7.06 1.00E-04 [84]
Pancreatic cancer PDAC vs matched normal 36 36 3.01 9.70E-05 [85]
doi:10.1371/journal.pone.0026439.t005
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and fold change measurements, provided by NextBio, were
recorded.
Gene Set Enrichment Analysis (GSEA) of Human Lung
Cancer Data Sets
Three lung cancer gene expression datasets were analyzed to
assess the relationships between Mmp10 levels, the cancer stem
cell phenotype and metastasis in human cancer. The first two data
sets (GSE11969 and GSE13213) are comprised of gene expression
measurements from NSCLC tumors. [46,47]. The third dataset
(GSE10799) contained expression values from human lung
adenocarcinoma samples that had produced metastasis in bone
tissue compared to samples that had not [34]. All three of the
microarray datasets were downloaded from GEO into the ‘‘R
statistical computing language’’ using the ‘‘GEOquery’’ package of
the ‘‘Bioconductor’’ software suite [48,49,50]. Quantile normal-
ization of the datasets was performed using the ‘‘preprocess core’’
module [49,51]. GSE11969 and GSE13213 were sorted according
to their Mmp10 expression values. Lung tumor samples in
GSE11969 were segregated into two sets. The first set contained
the 30 samples with the highest Mmp10 expression values and the
second set the 30 samples with the lowest Mmp10 expression
values. GSE13213 was treated in the same manner except samples
were separated into groups of 35 instead of 30. The size of the
groups was determined to maximize the statistical significance of
differential Mmp10 expression in each group as determined by a
Welch’s t-test.
Gene Set Enrichment Analysis (GSEA) was carried out on all of
the lung cancer gene expression datasets described above [52,53].
For each dataset, GSEA’s were performed using two groups of
gene sets that were available as part of the Molecular Signatures
Database (MSig) Version 3.0 (http://www.broadinstitute.org/
gsea/msigdb/index.jsp) [53]. The first collection of gene sets was
intended to measure each datasets’ degree of enrichment for the
cancer stem cell phenotype. This group of gene sets was selected
by searching the MSig database for signatures that contained the
terms ‘‘cancer’’ and ‘‘stem’’ within their descriptions. The second
collection of gene sets contained every signature listed in the MSig
database and was intended to explore the relationships among the
datasets in an untargeted fashion. In all GSEA’s, gene sets that
produced nominal p-values of less than 0.05 and false discovery
rates (FDRs) of less than 0.25 were considered to be significantly
enriched in the tested dataset.
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